Scientific Program
Program days will run as scheduled, on Central European Time (CET Time Zone) – UTC +1
| Day 1, March 2nd | |
|---|---|
| 13:00-13:15 | Opening welcome Congress co-chairs |
| 13:15-14:15 | Keynote Lectures |
| 13:15-13:45 | Advancements in AML immunotherapy: He Huang, China |
| 13:45-14:15 | Predicting response to CAR T cells in LBCL: Arnon Nagler, Israel |
| 14:15-15:45 | Session 1: Innovation in Immunotherapy |
| 14:15-14:35 | Linking the microbiome to CAR T cells responses: Florent Malard, France |
| 14:35-14:55 | Cytokine release syndrome after CAR T therapy: Yongxian Hu, China |
| 14:55-15:15 | CAR T treatment related to refractory/relapsed multiple myeloma: Mingming Zhang, China |
| 15:15-15:35 | Exploring the value of point-of-care development: Alvaro Urbano-Ispizua, Spain |
| 15:35-15:45 | Panel discussion |
| 15:45-17:15 | Session 2: Advanced Cellular Therapies |
| 15:45-16:05 | Will allogeneic CAR T cells revolutionize immunotherapy? Bhagirathbhai Dholaria, USA |
| 16:05-16:25 | Exploring the advantages of CAR NK cells over CAR T cells: Rizwan Romee, USA |
| 16:25-16:45 | The promise of induced pluripotent stem cells-derived CAR-immune cells: Jin Zhang, China |
| 16:45-17:05 | DESCAR-T data on the use of Axi Cel as a 2nd line treatment option for patients with LBCL: Gabriel Brisou, France |
| 17:05-17:15 | Panel discussion |
| Day 2, March 3rd | |
|---|---|
| 13:00-14:20 | Session 3: Disease-Specific Focus |
| 13:00-13:20 | Targeting solid tumors: selecting an example (e.g., gastric, pancreatic, glioblastoma, or liver cancer): Dongrui Wang, China |
| 13:20-13:40 | First-line treatment strategies for relapsed DLBCL: Rémy Duléry, USA |
| 13:40-14:00 | Multiple myeloma: timing and approaches: Mohamad Mohty, France |
| 14:00-14:20 | Panel discussion |
| 14:20-15:40 | Session 4: Practical Management in Immunotherapy |
| 14:20-14:40 | Strategies for preventing and treating CRS/ICANS in older patients: Antoine Capes, France |
| 14:40-15:00 | Infectious complications after CAR T cells: Eolia Brissot, France |
| 15:00-15:20 | CAR T cells hematotoxicity – Is inflammation the key? Marion Subklewe, Germany |
| 15:20-15:40 | Panel discussion |
| 15:40-16:30 | Session 5: Specific Approaches |
| 15:40-16:00 | Allogeneic HSCT as consolidation after immunotherapy: donor selection and personalized therapy: Yishan Ye, China |
| 16:00-16:20 | Strategies to prevent toxicities after CAR T cell therapy: Jordan Gauthier, USA |
| 16:20-16:30 | Panel discussion |
| 16:30-17:00 | Closing Lecture |
| From transplantation to CAR T: what have we learned? Didier Blaise, France |
|
| 17:00-17:15 | Summing-up remarks Congress co-chairs |